Despite high profile events such as the industry's showcase BIO 2006 in April and the annual meeting of the American Society of Clinical Oncology (ASCO) in June, they failed to generate any "buzz" for biotech investors in the second quarter. "For a number of reasons investor confidence in biotech
is at a low ebb," said G. Steven Burrill, CEO of Burrill & Company a
San Francisco based global leader in life sciences whose principal activities
are in Venture Capital, Merchant Banking and Media.